All In Biotech

Drug Trial Radar · NCT05565807

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 9, 2023

Primary completion

Dec 31, 2026

Study completion Feb 19, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • STI-6129Biological

    Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events(AEs)Time frame: Up to 2 years
  2. Overall response rate(ORR)Time frame: Up to 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital,Capital Medicine University

    Beijing, Beijing Municipality, China · Recruiting

  • Peking university Third hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The first affiliated hospital ,Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.